Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy

Dick C Chan, Gerald F Watts, Blai Coll, Scott M Wasserman, Santica M Marcovina, P Hugh R Barrett, Dick C Chan, Gerald F Watts, Blai Coll, Scott M Wasserman, Santica M Marcovina, P Hugh R Barrett

Abstract

Background Elevated lipoprotein(a) (Lp(a)), a low-density lipoprotein-like particle bound to the polymorphic apolipoprotein(a) (apo(a)), may be causal for cardiovascular disease. However, the metabolism of Lp(a) in humans is poorly understood. Methods and Results We investigated the kinetics of Lp(a)-apo(a) and low-density lipoprotein-apoB-100 in 63 normolipidemic men. The fractional catabolic rate ( FCR ) and production rate PR ) were studied. Plasma apo(a) concentration was significantly and inversely associated with apo(a) isoform size ( r=-0.536, P<0.001) and apo(a) FCR ( r=-0.363, P<0.01), and positively with apo(a) PR ( r=0.877, P<0.001). There were no significant associations between the FCR s of apo(a) and low-density lipoprotein-apoB-100. Subjects with smaller apo(a) isoform sizes (≤22 kringle IV repeats) had significantly higher apo(a) PR ( P<0.05) and lower apo(a) FCR ( P<0.01) than those with larger sizes. Plasma apo(a) concentration was significantly associated with apo(a) PR ( r=0.930, P<0.001), but not with FCR ( r=-0.012, P>0.05) in subjects with smaller apo(a) isoform size. In contrast, both apo(a) PR and FCR were significantly associated with plasma apo(a) concentrations ( r=0.744 and -0.389, respectively, P<0.05) in subjects with larger isoforms. In multiple regression analysis, apo(a) PR and apo(a) isoform size were significant predictors of plasma apo(a) concentration independent of low-density lipoprotein-apoB-100 FCR and background therapy with atorvastatin and evolocumab. Conclusions In normolipidemic men, the plasma Lp(a) concentration is predominantly determined by the rate of production of Lp(a) particles, irrespective of apo(a) isoform size and background therapy with a statin and a proprotein convertase subtilisin-kexin type 9 inhibitor. Our findings underscore the importance of therapeutic targeting of the hepatic synthesis and secretion of Lp(a) particles. Lp(a) particle catabolism may only play a modest role in determining Lp(a) concentration in subjects with larger apo(a) isoform size. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02189837.

Trial registration: ClinicalTrials.gov NCT02189837.

Keywords: apolipoprotein; cardiovascular disease risk factors; cholesterol‐lowering drugs; lipids and lipoprotein metabolism; low‐density lipoprotein.

Figures

Figure 1
Figure 1
Association between plasma apolipoprotein(a) (apo(a)) concentration and apo(a) isoform size (A), apo(a) fractional catabolic rate (FCR) (B), and apo(a)‐production rate (PR) (C) at baseline in the 63 subjects.
Figure 2
Figure 2
Association between plasma apolipoprotein(a) (apo(a)) concentration and apo(a) production rate (PR) and apo(a) fractional catabolic rate (FCR) at baseline in subjects with smaller apo(a) isoforms ≤22 kringle‐IV (KIV) (n=36, A and B, respectively) and larger apo(a) isoforms >22 KIV (n=27, C and D, respectively).
Figure 3
Figure 3
Association between plasma apolipoprotein(a) (apo(a)) concentration and apo(a) isoform size (A), apo(a) fractional catabolic rate (FCR) (B), and apo(a) production rate (PR) (C) in the 47 subjects on active treatments. ATV indicates atorvastatin; EVO, evolocumab.

References

    1. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta‐analysis of prospective studies. Circulation. 2000;102:1082–1085.
    1. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–1975.
    1. Kamstrup PR, Tybjaerg‐Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146–1156.
    1. Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5:524–533.
    1. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). J Lipid Res. 2016;57:1339–1359.
    1. Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR. Controlled study of the effect of proprotein convertase subtilisin‐kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J. 2018;39:2577–2585.
    1. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758–2763.
    1. Marcovina SM, Koschinsky ML. Lipoprotein(a) concentration and apolipoprotein(a) size: a synergistic role in advanced atherosclerosis? Circulation. 1999;100:1151–1153.
    1. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993;91:443–447.
    1. Jenner JL, Seman LJ, Millar JS, Lamon‐Fava S, Welty FK, Dolnikowski GG, Marcovina SM, Lichtenstein AH, Barrett PH, deLuca C, Schaefer EJ. The metabolism of apolipoproteins (a) and B‐100 within plasma lipoprotein (a) in human beings. Metabolism. 2005;54:361–369.
    1. Su W, Campos H, Judge H, Walsh BW, Sacks FM. Metabolism of apo(a) and apoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab. 1998;83:3267–3276.
    1. Demant T, Seeberg K, Bedynek A, Seidel D. The metabolism of lipoprotein(a) and other apolipoprotein B‐containing lipoproteins: a kinetic study in humans. Atherosclerosis. 2001;157:325–339.
    1. Frischmann ME, Ikewaki K, Trenkwalder E, Lamina C, Dieplinger B, Soufi M, Schweer H, Schaefer JR, König P, Kronenberg F, Dieplinger H. In vivo stable‐isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis. 2012;225:322–327.
    1. Diffenderfer MR, Lamon‐Fava S, Marcovina SM, Barrett PH, Lel J, Dolnikowski GG, Berglund L, Schaefer EJ. Distinct metabolism of apolipoproteins (a) and B‐100 within plasma lipoprotein(a). Metabolism. 2016;65:381–390.
    1. Havekes L, Vermeer BJ, Brugman T, Emeis J. Binding of LP(a) to the low density lipoprotein receptor of human fibroblasts. FEBS Lett. 1981;132:169–173.
    1. Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest. 1983;71:1431–1441.
    1. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990;85:1542–1547.
    1. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995;95:1403–1408.
    1. van Capelleveen JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein (a). J Lipid Res. 2016;57:1612–1618.
    1. Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, Tsimikas S. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016;10:594–603.
    1. Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Baseline and on‐statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient‐data meta‐analysis of statin outcome trials. Lancet. 2018;392:1311–1320.
    1. Croyal M, Tran TT, Blanchard RH, Le Bail JC, Villard EF, Poirier B, Aguesse A, Billon‐Crossouard S, Ramin‐Mangata S, Blanchard V, Nativel B, Chemello K, Khantalin I, Thedrez A, Janiak P, Krempf M, Boixel C, Lambert G, Guillot E. PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate. Clin Sci. 2018;132:1075–1083.
    1. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni‐Berthold I, Im K, Pineda AL, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER trial. Circulation. 2018. .
    1. Watts GF, Chan DC, Dent R, Somaratne R, Wasserman SM, Scott R, Burrows S, Barrett PHR. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation. 2017;135:338–351.
    1. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, Couderc R, Dati F, Rifai N, Sakurabayashi I, Tate JR, Steinmetz A. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46:1956–1967.
    1. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436–439.
    1. Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem. 2004;50:1364–1371.
    1. Hopewell JC, Seedorf U, Farrall M, Parish S, Kyriakou T, Goel A, Hamsten A, Collins R, Watkins H, Clarke R. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med. 2014;276:260–268.
    1. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest. 1980;65:1483–1490.
    1. Wade DP, Knight BL, Harders‐Spengel K, Soutar AK. Detection and quantitation of apolipoprotein(a) mRNA in human liver and its relationship with plasma lipoprotein(a) concentration. Atherosclerosis. 1991;91:63–72.
    1. White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for “null” lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem. 1994;269:9060–9066.
    1. Durovic S, März W, Frank S, Scharnagl H, Baumstark MW, Zechner R, Kostner GM. Decreased binding of apo‐lipoprotein(a) to familial defective apolipoprotein B‐100 (Arg3500Gln). J Biol Chem. 1994;269:30320–303255.
    1. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res. 2005;46:2681–2691.
    1. März W, Beckmann A, Scharnagl H, Siekmeier R, Mondorf U, Held I, Schneider W, Preissner KT, Curtiss LK, Gross W, Huttinger M. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor‐related protein/alpha 2‐macroglobulin receptor. FEBS Lett. 1993;325:271–275.
    1. Ellis KL, Boffa MB, Sahebkar A, Koschinsky ML, Watts GF. The renaissance of lipoprotein(a): brave new world for preventive cardiology? Prog Lipid Res. 2017;68:57–82.
    1. Csete ME, Doyle JC. Reverse engineering of biological complexity. Science. 2002;295:1664–1669.
    1. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler Thromb Vasc Biol. 2017;37:580–588.
    1. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71:1036–1043.
    1. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692–711.
    1. Cauza E, Kletzmaier J, Bodlaj G, Dunky A, Herrmann W, Kostner K. Relationship of non‐LDL‐bound apo(a), urinary apo(a) fragments and plasma Lp(a) in patients with impaired renal function. Nephrol Dial Transplant. 2003;18:1568–1572.
    1. Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2016;57:340–351.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit